The Patients for Biologics Safety and Access (PBSA) is calling on the FDA to revise its prescriber-directed online educational materials on biosimilars. However, not all patient groups agree with PBSA’s stance.
The Patients for Biologics Safety and Access (PBSA) is calling on the FDA to revise its prescriber-directed online educational materials on biosimilars.
The PBSA’s feedback to the FDA includes a red-lined document of the FDA’s materials. The organization’s proposed edits include, among others, adding a statement that the FDA does not require data on the safety of multiple switches to and from a reference product or other approved biosimilars or interchangeable products and adding a side-by-side comparison chart showing differences in the application and approval process for biosimilars versus their reference products.
It also proposes adding the phrase “the assumption is that” before the statement “It is scientifically justified to rely on certain existing scientific knowledge about the safety and effectiveness of the reference product to support approval.” PBSA also asks the FDA to delete a statement that prescribers and patients should have no concerns about using biosimilars instead of reference products.
However, not all patient groups agree with PBSA’s stance. Louis Tharp, co-founder and executive director of the Global Healthy Living Foundation and its arthritis community, CreakyJoints, told The Center for Biosimilars® in an interview that his organizations strongly disagrees with PBSA on this matter.
“First of all, [patient groups] all correspond with FDA, CDC, and other agencies—[both] state and federal. We think that’s important. The difference here is that we don’t put out a press release about it. Publicizing the details of an educational program makes us wonder whether the PBSA is trying to disparage biosimilars. If that was the intent of that news release, we have to stand up and say we can’t agree with that,” said Tharp. “We need to understand what the motives are, and we need to be sure that biosimilars have every opportunity."
While Tharp said that he would welcome continued efforts by the FDA to help pave the way for greater adoption of biosimilars—including continued educational efforts—so far, he would give the FDA and Commissioner Scott Gottlieb, MD, an “A” for their record on biosimilars.
Tharp also had qualms about PBSA’s call for congressional oversight hearings on the safety of biosimilars. “We follow biosimilars in Europe, Asia, and the United States, said Tharp. “The safety record of biosimilars in Europe and Asia is exemplary. It’s stellar.”
Furthermore, a representative of the International Foundation for Autoimmune & Autoinflammatory Arthritis (IFAA), a member organization of PBSA, was quoted in PBSA’s press release as speaking in favor of the proposed changes to the FDA’s materials. However, the representative told The Center for Biosimilars® via email that IFAA stands in support of both biosimilars and the FDA, and that IFAA has instructed the PBSA to remove the quote from its materials.
The Biosimilars Forum also weighed in; Juliana M. Reed, president of the Biosimilars Forum, told The Center for Biosimilars® in an email that “There are more than 700 million patient days of data worldwide that demonstrate biosimilars are as safe and effective as their reference products. Europe has benefited from biosimilars for over 10 years, and biosimilars have lowered drug costs and increased patient access in over 80 countries." Reed added that "The Forum supports the efforts by the FDA to help health care providers gain a better understanding of these important products and the approval process they undergo."
PBSA could not be reached for comment.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.